Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
$7.74
-7.6%		$6.98
$0.18
▼
$10.99
$318.99M0.639,724 shs5,631 shs
CureVac N.V. stock logo
CVAC
CureVac
$4.66
$4.66
$3.13
▼
$5.72
$1.05B1.77992,546 shsN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$16.66
-2.3%		$17.62
$12.12
▼
$35.34
$1.04B2.4787,978 shs378,883 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$11.46
-4.4%		$13.53
$1.50
▼
$16.33
$1.12B0.932.00 million shs1.90 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
-7.64%+11.98%-15.87%+514.29%+841.09%
CureVac N.V. stock logo
CVAC
CureVac
0.00%0.00%0.00%0.00%-13.54%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-2.34%+0.91%+0.85%+8.68%-36.75%
Replimune Group, Inc. stock logo
REPL
Replimune Group
-4.42%+5.52%-11.57%+18.14%+38.07%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
$7.74
-7.6%		$6.98
$0.18
▼
$10.99
$318.99M0.639,724 shs5,631 shs
CureVac N.V. stock logo
CVAC
CureVac
$4.66
$4.66
$3.13
▼
$5.72
$1.05B1.77992,546 shsN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$16.66
-2.3%		$17.62
$12.12
▼
$35.34
$1.04B2.4787,978 shs378,883 shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$11.46
-4.4%		$13.53
$1.50
▼
$16.33
$1.12B0.932.00 million shs1.90 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
-7.64%+11.98%-15.87%+514.29%+841.09%
CureVac N.V. stock logo
CVAC
CureVac
0.00%0.00%0.00%0.00%-13.54%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-2.34%+0.91%+0.85%+8.68%-36.75%
Replimune Group, Inc. stock logo
REPL
Replimune Group
-4.42%+5.52%-11.57%+18.14%+38.07%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
0.00
N/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
1.00
SellN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2.67
Moderate Buy$36.46118.86% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
2.60
Moderate Buy$12.004.71% Upside

Current Analyst Ratings Breakdown

Latest BFNH, CVAC, REPL, and JANX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/19/2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/16/2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
10/5/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
8/26/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$20.00 ➝ $21.00
8/24/2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradePeer Perform ➝ Outperform$23.00
8/24/2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
8/12/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
8/11/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/7/2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$35.00
8/7/2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$58.00 ➝ $55.00
8/7/2026
Replimune Group, Inc. stock logo
REPL
Replimune Group
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeNeutral ➝ Outperform$12.00
(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/A($0.02) per shareN/A
CureVac N.V. stock logo
CVAC
CureVac
$70.74M14.78$0.99 per share4.73$3.36 per share1.39
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
$10M101.86N/AN/A$15.91 per share1.05
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$2.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
-$1.29M$0.01774.77N/AN/AN/A-84.67%-16.36%N/A
CureVac N.V. stock logo
CVAC
CureVac
$175.50M$0.726.47N/AN/A199.92%-23.03%-19.09%N/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$113.62M-$1.64N/AN/AN/AN/A-11.89%-11.13%11/5/2026 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$313.94M-$3.15N/AN/AN/AN/A-159.32%-90.84%10/28/2026 (Estimated)

Latest BFNH, CVAC, REPL, and JANX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.4737N/AN/AN/A$8.03 millionN/A
10/28/2026Q2 2027
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.7840N/AN/AN/A$1.00 millionN/A
8/14/2026Q1 2027
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.6940-$0.72-$0.0260-$0.72$13.60 millionN/A
8/10/2026Q2 2026
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A$0.01N/A$0.01N/AN/A
8/6/2026Q2 2026
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
-$0.2513-$0.35-$0.0987-$0.35$19.08 million$10.27 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/AN/AN/AN/AN/A
CureVac N.V. stock logo
CVAC
CureVac
N/AN/AN/AN/AN/A
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A
25.41
25.41
CureVac N.V. stock logo
CVAC
CureVac
0.03
3.70
3.69
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
N/A
16.35
16.35
Replimune Group, Inc. stock logo
REPL
Replimune Group
1.00
5.23
5.23

Institutional Ownership

CompanyInstitutional Ownership
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
N/A
CureVac N.V. stock logo
CVAC
CureVac
17.26%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
75.39%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%

Insider Ownership

CompanyInsider Ownership
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
39.54%
CureVac N.V. stock logo
CVAC
CureVac
2.15%
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
7.90%
Replimune Group, Inc. stock logo
REPL
Replimune Group
5.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioForce Nanosciences Holdings Inc. stock logo
BFNH
BioForce Nanosciences
338.07 million23.02 millionNot Optionable
CureVac N.V. stock logo
CVAC
CureVac
880224.34 million219.52 millionNo Data
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
11361.14 million56.31 millionOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
46593.80 million88.73 millionOptionable

Recent News About These Companies

Replimune Group (REPL) Projected to Post Earnings on Wednesday
October 23 at 2:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148245
Replimune Group (REPL) Expected to Release Earnings on Wednesday
October 23 at 2:10 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-replimune-group-repl-expected-to-release-earnings-on-wednesday-2026-10-23/
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
October 22 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386248/0/en/replimune-to-report-the-fiscal-second-quarter-2027-financial-results-and-provide-corporate-update-on-october-28-2026.html
Replimune Group (REPL) Stock Looks Rich After A 141% Run
October 17, 2026  |  sg.finance.yahoo.comhttps://sg.finance.yahoo.com/news/replimune-group-repl-stock-looks-161448106.html
Brokerages set USD 12.00 target for Replimune stock
October 15, 2026  |  ad-hoc-news.deA
Replimune Group (NASDAQ:REPL) Stock Falls 6.7% - What's Next?
October 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-replimune-group-nasdaq-repl-stock-falls-67-whats-next-2026-10-13/
Replimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Target Price of $12.00
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114069
Replimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Price Target of $12.00 According to Brokerages
October 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-replimune-group-inc-nasdaq-repl-stock-has-consensus-price-target-of-1200-according-to-brokerages-2026-10-13/
Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/replimune-group-repl-launches-tudriqev-151227981.html
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
October 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/05/3374835/9788/en/bronstein-gewirtz-grossman-llc-urges-replimune-group-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
Replimune Group, Inc. Announces Tudriqev? Now Commercially Available in the United States for Advanced Melanoma
October 2, 2026  |  marketscreener.comM
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3373980/0/en/replimune-class-action-deadline-monday-bragar-eagel-squire-p-c-urgently-reminds-replimune-group-inc-investors-to-contact-the-firm-seeking-lead-plaintiff-role-before-october-5th.html
Replimune's TUDRIQEV now available in U.S. for advanced melanoma
October 1, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Replimunes+TUDRIQEV+now+available+in+U.S.+for+advanced+melanoma/27135726.html
Replimune Receives Approval to Launch Tudriqev in the US for Melanoma
October 1, 2026  |  marketscreener.comM
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373368/0/en/replimune-announces-tudriqev-now-available-in-the-u-s-for-advanced-melanoma.html
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373215/9788/en/bronstein-gewirtz-grossman-llc-urges-replimune-group-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL
October 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/suewallst-reminds-replimune-group-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-5-2026---repl-302895607.html
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky
September 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/repl-shareholder-alert-investors-with-losses-may-seek-to-lead-the-class-action-in-replimune-group-inc-securities-lawsuit---contact-levi--korsinsky-302894654.html
Bank of America Corp DE Purchases New Holdings in Replimune Group, Inc. $REPL
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-purchases-new-holdings-in-replimune-group-inc-repl-2026-09-30/
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371399/0/en/replimune-class-action-deadline-monday-bragar-eagel-squire-p-c-urgently-reminds-replimune-group-inc-investors-to-contact-the-firm-seeking-lead-plaintiff-role-before-october-5th.html
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371353/1087/en/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-replimune-group-inc-of-class-action-lawsuit-and-upcoming-deadlines-repl.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioForce Nanosciences stock logo

BioForce Nanosciences OTCMKTS:BFNH

$7.74 -0.64 (-7.64%)
As of 10/23/2026 03:49 PM Eastern

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.

CureVac stock logo

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)
As of 10/22/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Janux Therapeutics stock logo

Janux Therapeutics NASDAQ:JANX

$16.66 -0.40 (-2.34%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$16.65 -0.01 (-0.06%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$11.46 -0.53 (-4.42%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$11.48 +0.01 (+0.13%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas